Over the last 10 years, there has been a 242% increase in the number of babies born with the drug withdrawal syndrome known as Neonatal Opioid Withdrawal Syndrome (NOWS), also referred to as neonatal abstinence syndrome (NAS; [@bib11]; [@bib44]). NOWS is characterized by increased central nervous system excitability and hyperirritability, such as excessive crying, hypertonia, tremors, sleep disturbances, gastrointestinal problems, poor feeding, vomiting and diarrhea, respiratory distress, sweating, and sneezing ([@bib14]; [@bib29]). Not all newborns exposed to opioids *in utero* develop NOWS. The incidence of NOWS is highly variable, with estimates ranging from 50 to 80% ([@bib29]; [@bib44]). This variability can likely be attributed to a variety of factors including the type of opioid to which the infant was exposed (e.g., heroin, buprenorphine, methadone), the number of newborns who require pharmacological treatment, and the diverse ways in which NOWS is assessed ([@bib44]). There is a critical gap in our understanding of the neurodevelopmental and psychiatric consequences of prenatal exposure to opioids. The existing literature is also plagued by low sample sizes, a lack of consideration of confounding stressors and/or effects of other substances over-and-above opioid exposure, and a lack of appropriate comparison groups. The aim of this review is to: (1) review the pathophysiology of prenatal opioid exposure; (2) outline additional stressors to which the fetus may be exposed; (3) briefly review the extant literature on prenatal opioid exposure and neurodevelopmental outcomes; (4) describe how outcomes could vary by infant sex; and (5) introduce an agenda for future research focused on developmental sequelae of prenatal opioid exposure.

1. Pathophysiology of prenatal opioid exposure {#sec1}
==============================================

Opioids are defined as any class of drug that bind to G-protein coupled receptors, of which there are four subtypes: μ (mu), Κ (kappa) and δ (delta), and nociception-orphanin FQ ([@bib44]). These opioids include "street drugs" such as heroin, as well as prescription pain relievers such as oxycodone, hydrocodone, codeine, morphine, methadone, and buprenorphine. Methadone and buprenorphine are the two most common medications given to pregnant women addicted to opioids ([@bib44]). Methadone is a complete μ-opioid receptor agonist and results in heroin-like effects ([@bib12]). However, because of its long half-life, it typically prevents withdrawal effects if patients receive a daily dose. Buprenorphine is a partial μ-opioid receptor agonist and complete Κ-receptor antagonist. It can therefore prevent withdrawal symptoms without resulting in strong euphoric effects ([@bib12]; [@bib44]). Because it is a partial, as opposed to complete agonist, it has a ceiling effect beyond which a higher dose is not more effective ([@bib44]).

We first describe direct effects of opioids on the mother. Opioids are metabolized in the liver and also cross the blood-brain barrier ([@bib69]). Opioids act on the central nervous system and bind at endogenous opioid receptors ([@bib5]; [@bib7]). Direct behavioral effects of opioid use in adults include analgesia, lowered anxiety, euphoria, and drowsiness ([@bib69]). Physiologically, respiratory depression and intestinal peristalsis also occur ([@bib69]). Among pregnant women, opioids can alter maternal glucose regulation, and decrease arterial pressure and uterine blood flow ([@bib53]). These effects, in addition to depressed respiratory function, can affect the amount of oxygen the fetus receives *in utero* ([@bib53]). Opioid-induced maternal hypotension can also reduce uterine blood flow ([@bib53]).

Opioid receptor concentrations fluctuate across development ([@bib12]). Opioid binding sites are present in the fetus before birth and direct exposure effects are likely mediated by the presence of these opioid receptors as well as overstimulation of μ opioid receptors ([@bib37]). In rat fetal neurons, methadone binding occurs at rates 2--14 times higher than maternal neurons ([@bib43]). Following exposure to opioids, there are direct effects on fetal cardiovascular, respiratory, neurobehavioral, metabolic and neuroendocrine systems ([@bib53]). For example, fetuses exposed to buprenorphine (*n* = 6) showed higher fetal heart rate variability, more accelerations in fetal heart rate, and greater coupling between heart rate and movement in the second trimester compared to methadone-exposed fetuses (*n* = 11), and in the third trimester fetuses exposed to buprenorphine exhibited more motor activity ([@bib25], [@bib4s]). After birth, newborns with prenatal opioid exposure also exhibited greater heart rate variability during nutritive and non-nutritive sucking compared to non-exposed controls ([@bib18]).

These direct effects of opioids on the mother are mediated via placenta transfer of opioids from the woman to the fetal compartment. Indirect exposure therefore occurs via alterations in maternal-placental physiology ([@bib53]). The opioids meperidine, morphine and fentanyl can be detected in cord blood, neonatal plasma, and neonatal urine ([@bib53]). Methadone and, to a lesser extent, buprenorphine, crosses the human placenta, and this permeability is dependent on the number of tissue layers between fetal and maternal blood ([@bib12]). There is wide variability across women in the degree to which methadone is metabolized by the placenta, which could contribute to the range of neurodevelopmental outcomes seen in newborns with prenatal exposure to methadone ([@bib41]). These outcomes include intrauterine growth restriction, placental abruption, and preterm birth ([@bib52]).

In rats, prenatal morphine exposure has been shown to affect the migration and survival of rat neurons ([@bib62]). Morphine increases apoptosis in human fetal microglia and neurons and disrupts neural maturation ([@bib51]; [@bib54]). Prenatal exposure to opioids such as methadone and buprenorphine can also impact myelination ([@bib46]; [@bib56]). Opioid receptors are found on the surface of oligodendrocytes, which are involved in the production of myelin ([@bib56]). Prenatal exposure to methadone in rodents sped up the timing of myelination in the corpus callosum and accelerated the maturation of preoligodendrocytes ([@bib56]). Prenatal exposure to moderate levels of buprenorphine in rodents also resulted in precocious myelination as well as the thinning of the myelin sheath ([@bib46]), and exposure to higher doses resulted in a reduction of myelinated axons in the rat corpus callosum ([@bib46]). This accelerated myelination has the potential of dysregulating normal neural connectivity in the fetal brain ([@bib56]).

Prolonged exposure to opioids *in utero* suppresses opioid G protein coupled receptors which in turn leads to increases in adenyl cyclase activity and subsequent dysregulation of multiple neuroendocrine pathways ([@bib31]). Withdrawal from opioids in the newborn results in increased levels of norepinephrine, corticotrophin, noradrenaline, and acetylcholine. Increases in these stress neurotransmitters are related to tremors and hyperthermia. Decreases in dopamine and serotonin have also been observed in newborns exposed to opioids *in utero*, which likely plays a role in hyperirritability and sleep fragmentation, respectively ([@bib31]).

We have described here direct effects of opioids on the mother and indirect (e.g., via placenta transfer) effects of prenatal opioid exposure on the fetus. A third, and largely unexplored pathophysiology of prenatal opioid exposure, may be indirect effects that occur due to exposure to early life stress which often covaries with prenatal opioid exposure.

2. Prenatal opioid exposure and the effects of early life stress {#sec2}
================================================================

In [Fig. 1](#fig1){ref-type="fig"} we highlight the important stressors that mothers with opioid use disorders are disproportionately more likely to experience compared to mothers who are not using opioids while pregnant. Children exposed to opioids *in utero* also often experience the effects of poverty, maternal psychopathology and emotion dysregulation, disruptions in maternal care, and problematic (e.g., insensitive) interactions with their primary caregiver ([@bib19]). Women who use opioids while pregnant are also more likely to have poor nutrition, decreased access to and compliance with the health care system, and increased exposure to violence ([@bib5]). These women are also more likely to have a history of trauma ([@bib45]). Approximately 50--80% of women with substance use disorders have also experienced physical, sexual, and/or emotional abuse ([@bib45]) which is associated with neuroendocrine dysregulation ([@bib8]).Fig. 1Factors that may exert programming effects on the developing fetus exposed to opioids *in utero.* Adapted from [@bib2s].Fig. 1

Women who use opioids while pregnant are also more likely to use other substances, such as nicotine, alcohol, antidepressants, and benzodiazepines compared to pregnant women who aren\'t using opioids ([@bib20]; [@bib68]). Furthermore, they are more likely to experience a range of psychiatric comorbidities in addition to their substance use disorder such as anxiety, depression, and bipolar disorder ([@bib67]). Given the high rates of polysubstance use and mental health comorbidities among women with opioid use disorders it is necessary to examine the shared mechanisms underlying development of these disorders. In other words, a transdiagnostic approach to investigating processes that give rise to the constellation of psychiatric symptoms among women who use opioids while pregnant is needed ([@bib15]).

*Maternal emotion dysregulation*. We highlight here the importance of assessing emotion dysregulation in pregnant women with an opioid use disorder. Emotion dyregulation is a transdiagnostic vulnerability for a variety of psychiatric disorders, including substance use disorders ([@bib4]). It is a multi-faceted construct that includes a lack of awareness and acceptance of emotions, an inability to control behaviors when experiencing distress, a lack of access to adaptive strategies for regulating emotion, and an unwillingness to experience emotional distress ([@bib4]; [@bib35]). Maternal emotion dysregulation is both a cause and consequence of stress and is often seen among those with anxiety, depression, borderline personality disorder, and bipolar disorder, discrete diagnoses that are commonly found among women with opioid use disorders ([@bib67]).

Adults with substance use disorders experience greater overall levels of emotion dysregulation compared to adults who do not use substances ([@bib2]; [@bib66]). They report difficulties accepting and regulating their emotions, engaging in goal-directed behavior, controlling impulsive behavior when distressed, and identifying appropriate strategies for regulating emotions ([@bib2]). These symptoms are heightened if individuals with substance use disorders also engage in self-harm ([@bib1]). Furthermore, emotion dysregulation may mediate the association between childhood trauma and later substance use disorders ([@bib66]). Emotion dysregulation may therefore be a key construct that could explain the etiology of opioid use disorders in pregnant women, particularly those with an early trauma history. For researchers interested in examining maternal effects on child risk, including impaired developmental outcomes in children with prenatal opioid exposure, it may be worthwhile including an assessment of this construct.

Importantly, emotion dysregulation can be assessed at multiple levels of analysis, including self-reports, behavioral observations, laboratory tasks, and biomarkers. One key biomarker of risk for emotion dysregulation is respiratory sinus arrhythmia (RSA; also known as high frequency heart rate variability; HF-HRV), which is an index of parasympathetic nervous system functioning ([@bib4]). RSA is a measure of the natural beat-to-beat variability in heart rate that occurs with respiration. Specifically, heart rate increases during inhalation, and decreases with exhalation and RSA indexes the component of this variability that is due to parasympathetic influences ([@bib6]). Changes in RSA (increases or decreases) are thought to occur in response to stress ([@bib3]). RSA has been assessed in women in a methadone maintenance treatment program ([@bib24]). Jansson and colleagues found that any changes in RSA in response to methadone use in the mother were predictive of symptoms of NOWS. Mothers with no change in RSA in response to methadone administration were significantly less likely to have infants with symptoms of NOWS ([@bib24]). It may therefore be that changes in RSA in response to opioid administration was experienced as a stressor for these women, with consequences for the development of NOWS in the fetus.

Studies that have examined these factors, including maternal psychopathology, in addition to prenatal opioid exposure have found some support for the hypothesis that the effect of opioids no longer predicts offspring cognitive outcomes after controlling for associated stressors ([@bib19]; [@bib39]). For example, [@bib19] found that the effects of opioid exposure on poorer mental development outcomes, as assessed using the Bayley scales of mental and motor development in early childhood, were no longer significant after controlling for social-environmental risk factors like low maternal education, low family SES, and maternal-infant interactions. [@bib39] likewise found that the effects of opioid exposure on psychomotor development using the Bayley were no longer significant when controlling for covariates such as SES and quality of the home environment. These findings highlight the need to consider "confounds," such as early life stress exposure and sociodemographic risk and also suggest the need to consider potential programming effects. Indeed, prenatal programming of fetal stress response systems may be an additional pathway by which prenatal opioid exposure contributes to risk for impaired developmental outcomes.

3. Programming effects of prenatal opioid exposure {#sec3}
==================================================

As reviewed above, prenatal opioid exposure does not occur in isolation. In addition to the direct and indirect pathophysiological effects of prenatal opioid exposure, the fetus is more likely to be exposed to high levels of prenatal stress, which can exert programming effects on stress response systems, including the neuroendocrine system. We argue here that exposure to opioids prenatally and associated stressors could disrupt *in utero* homeostasis and result in adjustments that confer immediate survival advantage, with potential costs to long-term health ([@bib34]).

The programming hypothesis as it relates to prenatal substance exposure was originally proposed by Lester and Padbury in reference to children with prenatal cocaine exposure and it can be extended to children with prenatal opioid exposure ([@bib34]). It has been well-documented that early life stress impacts functioning of the hypothalamic-pituitary-adrenal (HPA) axis in the fetus and in early childhood (for reviews, see [@bib16]; [@bib17]; [@bib40]). It is therefore plausible that early life stress in addition to prenatal opioid exposure could exert additive or interactive programming influences on fetal HPA axis functioning. Paraventricular corticotrophin releasing hormone neurons, which activate the hypothalamic-pituitary-adrenal (HPA) axis, express μ-opioid receptors and are modulated by β-endorphin neurons ([@bib63]). Individuals expressing the μ-opioid receptor variant ASP40 have been shown to have disruptions in HPA axis functioning and altered responses to other physiological processes regulated through activation of the μ-opioid receptor ([@bib63]). Furthermore, removing the endogenous inhibitory opioid tone using naloxone, an opioid receptor antagonist, induces a rise in ACTH and cortisol ([@bib64]). In humans, those who are addicted to opioids show a blunted HPA axis response to stress ([@bib50]). The HPA axis tends to be more reactive during a period of withdrawal and shows the typical response to stress during treatment with a methadone maintenance program ([@bib13]).

These effects on the HPA axis could also extend to the postnatal period via disruptions in maternal caregiving. Rodent models suggest that the infant neuroendocrine system can be programmed by maternal caregiving behaviors such as licking and grooming and arched back nursing ([@bib65]). Some studies (though not all; [@bib26]) have found that women with substance use disorders are less sensitive when interacting with their infants ([@bib33]). For example, LaGasse and colleagues found that mothers who used cocaine while pregnant were less flexible and engaged, and also exhibited more activity with their infants during a feeding interaction compared to mothers who had not used cocaine while pregnant ([@bib33]). Children exposed to cocaine and opioids were also less likely to be securely attached compared to infants exposed to drugs other than cocaine and opioids ([@bib48]). In an independent sample, [@bib3s] found that mothers who used cocaine while pregnant showed more negative affect and less sensitivity when interacting with their 13-month-old infants. It is therefore possible that both prenatal and postnatal programming can alter the neuroendocrine and associated stress response systems among children with prenatal opioid exposure.

4. Prenatal opioid exposure effects on genetic, epigenetic, and neurodevelopmental outcomes {#sec4}
===========================================================================================

There is a dearth of information about the short and long-term neurodevelopmental effects of prenatal exposure to opioids in humans, and even less is known about effects on the developing infant brain. The vast majority of information comes from short-term follow-up studies, and includes clinical obstetric and pediatric outcomes such as birth weight, head circumference, and APGAR scores. It appears as though the effect of prenatal opioid exposure on the neurodevelopment of the neonate depends on a wide range of factors, including type of opioid (e.g., buprenorphine, methadone, or heroin) as well as associated early life stressors, such as maternal education and socioeconomic status. In one of the first studies on prenatal opioid exposure, [@bib26] found that methadone-exposed neonates (*n* = 29) were more jittery, had more tremors, and were more tense, active, and could put their hand to their mouth more easily compared to control infants (*n* = 37). [@bib19] followed these infants to two years of age and found no differences in cognitive outcomes between methadone-exposed and unexposed infants, though the exposed infants had poorer motor outcomes.

Coyle and colleagues (2012) found similar newborn neurobehavioral effects when comparing methadone-expose to buprenorphine-exposed newborns, with infants exposed to buprenorphine showing better newborn neurobehavioral outcomes compared to infants exposed to methadone. In another study comparing methadone-exposed (*n* = 11) and buprenporphine-exposed (*n* = 10) newborns using the NICU Network Neurobehavioral Scale (NNNS), newborns exposed to buprenorphine had higher arousal and excitability levels on postnatal days 5 and 7 (but not postnatal day 3, 10, or 14), compared to methadone-exposed newborns ([@bib27]). Furthermore, infants requiring treatment for NAS/NOWS showed poorer quality of movement, excitability, and lethargy scores compared to exposed newborns who did not need treatment, regardless of the type of opioid to which they were exposed ([@bib27]).

[@bib5s] studied three buprenorphine-exposed infants and found that they had typical birth outcomes, mild symptoms of NOWS, and required no pharmacological treatment. In a study of only buprenorphine-exposed newborns, Velez and colleagues found that greater exposure to buprenorphine was related to poor quality of movement and self-regulation, and more central nervous systems signs of stress at day 3. They found no differences in newborn neurobehavioral outcomes as assessed by the NNNS between infants who required pharmacotherapy for NOWS and those who did not require treatment on day 3. We only found two studies that compared neurodevelopmental effects in infants who received treatment for NOWS compared with those who did not. [@bib1s] discovered that, at an average of 55 days old, infants treated for NOWS (*n* = 28) had lower language and cognition scores compared to a historical control. This study should be interpreted with caution, however, given that infants were assessed at a mean age of 55 days, when it is difficult to capture variability in language and cognition using the Bayley. [@bib21] examined differences in neurodevelopmental outcome using the NNNS among 6-week old infants with prenatal methadone exposure who did (*n* = 23) or did not (*n* = 16) require pharmacological treatment for NOWS compared to a demographically matched control group (*n* = 21; [@bib21]). Infants who were exposed to methadone and who required treatment had more difficulty self-regulating and had poorer quality movement compared to an unexposed control and compared to infants who were exposed but did not require treatment ([@bib21]).

There is a small, but growing literature on genetic and epigenetic predictors of NOWS. Epigenetic methods can be useful in uncovering the mechanisms by which prenatal opioid exposure could lead to impaired neurodevelopmental outcome. Most of the focus thus far has been on epigenetic variation in the mu-opioid receptor gene in infants with NOWS ([@bib57]). Greater methylation at specific CpG sites on *OPRM1* was associated with greater need for medications to treat NOWS ([@bib57]) and see ([@bib60], [@bib61]) for a partial replication of these findings in an independent sample. In an independent sample, [@bib38] also found that increased DNA methylation in *OPRM1* was found among infants exposed to opioids *in utero* and that variability in DNA methylation of *ABCB1,* and *CYP2D6* related to prenatal opioid exposure. [@bib58] identified single nucleotide polymorphisms associated with NOWS severity in *PNOC* and *OPRK1*, genes from the opioid-receptor family. In a partial replication study, infants with a specific allele of the *PNOC* gene and specific alleles of the maternal *COMT* gene were less likely to require treatment as infants ([@bib59]). These findings indicate that there may be genetic indicators of risk for NOWS.

There are very few longitudinal follow-up studies with opioid-exposed infants. In one such study with 72 exposed and 58 comparison (unexposed) infants, the difference in IQ between female infants with and without prenatal opioid exposure increased from 1 to 8.5 years, even when controlling for foster care placement and heroin exposure, while boys with prenatal opioid exposure exhibited consistently lower levels of IQ over time compared to unexposed control boys ([@bib42]). In a study of only children with prenatal opioid exposure, Kaltenbach and colleagues found no differences in cognitive outcomes using the Bayley at three years of age between methadone-exposed and buprenorphine-exposed preschoolers ([@bib30]). At two years of age, [@bib36] found that methadone-exposed infants showed poorer inhibitory control. At 4 years methadone-exposed infants showed poorer short-term memory and inhibition, though these effects were partially explained by maternal education ([@bib32]; [@bib36]), maternal benzodiazepine use ([@bib36]), and maternal employment ([@bib32]).

It is unclear what the effects of prenatal opioid exposure may be on neurodevelopment given that the sample sizes tend to be low and few studies control for confounding factors like maternal psychopathology, polysubstance use, maternal nutrition, or socioeconomic status. Those that have controlled for these factors tend to find that the effects of opioids are no longer significant. Even fewer studies have controlled for the effects of polysubstance exposure. In other words, it is unknown whether the neurodevelopmental outcomes are due to opioids, the effects of other stressors, or the effects of other drugs, like nicotine. For example, in a retrospective chart review, [@bib6s] found that prenatal nicotine exposure, in addition to opioid exposure, type of opioid used, and selective serotonin reuptake inhibitor exposure was related to increased likelihood of developing NOWS. Large sample sizes are thus needed to try to disentangle the effects of the opioid on neurodevelopment above and beyond additional substances and associated environmental stressors.

5. Sex differences in response to prenatal opioid exposure {#sec5}
==========================================================

There is very little known about how the effects of prenatal opioid exposure may vary by infant sex, and the vast majority of studies are underpowered to detect sex differences. In studies with human newborns, males showed more symptoms of NOWS, and the symptoms they did express were more severe. As a result they received more pharmacological treatment compared to females ([@bib23]). In a study of newborn neurobehavioral outcomes, males exposed to opioids prenatally had higher scores on habituation, a measure of the neonate\'s ability to tune out external stimuli, compared to females exposed prenatally to opioids ([@bib27]). In a large cohort study that included a review of 102,695 medical records, Charles and colleagues ([@bib9]) found that males were more likely than females to be diagnosed with NOWS. However, no sex differences in NOWS severity were identified.

The theory of a viability-vulnerability tradeoff proffered by Sandman and colleagues ([@bib47]) is the only theory to date describing how sex differences due to fetal programming may occur. According to this hypothesis, prenatal exposure to stress could affect males by decreasing their viability and making it more likely that they exhibit maturational delays. This hypothesis supports the above reviewed finding by [@bib23]. While females may be more likely to survive a stressful prenatal environment, the effects of this exposure on developmental outcomes may be subtle and they may be at increased likelihood of experiencing fear and anxiety as a direct consequence of this exposure. While the literature on sex differences in prenatal opioid exposure is scarce, it will be important to consider in future work whether males exposed to opioids are more likely to show developmental delays while females could be more likely to show increases in fear and anxiety, as predicted by the theory of viability-vulnerability tradeoff ([@bib47]).

5.1. Future research priorities {#sec5.1}
-------------------------------

Substance use disorders are complex illnesses and there are a number of challenges associated with designing and conducting rigorous research on women who use substances while pregnant, and on the neurodevelopmental consequences of that use for the child ([@bib29]). First, very few studies examine maternal characteristics that predict newborn and infant neurodevelopmental outcomes. It will be important in future research to include comprehensive assessments of the mother, including her mental health and trauma history, as well as a detailed substance use history that can be verified using toxicology screens. Another novel approach is to examine whether maternal physiological stress signs are predictive of NOWS symptom severity ([@bib24]). For example, Jansson and colleagues found that any maternal response in the parasympathetic nervous system to administration of methadone was positively related to NOWS symptom severity and need for treatment. Individual differences in maternal parasympathetic response to methadone treatment may provide the field with more information about which children are at risk for developing NOWS.

In designing studies with humans, it will be nearly impossible to study women who are solely using opioids. Polysubstance use is the rule rather than the exception ([@bib29]) and studies can either covary for the effects of other substances, such as antidepressant exposure or exposure to nicotine, or create a cumulative substance exposure "risk" score (see for example ([@bib10]). Studies attempting to examine effects of prenatal opioid exposure will therefore benefit from maternal report of substance use in addition to toxicology screens at birth.

There is also no standardized assessment of NOWs that has widespread acceptance in the prenatal opioid literature. A number of studies use the Finnegan or an adaptation of the Finnegan (see for example [@bib23]), though there is wide variability in the way clinicians diagnose and treat NOWS ([@bib44]). In addition, the Finnegan has been shown to have poor psychometric properties ([@bib28]). Short, standardized, reliable, and valid assessments for the diagnosis of NOWS, especially ones that can be easily used by pediatricians and neonatologists, are sorely needed.

The studies examining predictors of NOWS symptom severity tend to be retrospective. While work on the genetic and epigenetic predictors of NOWS is growing, there are very few studies examining prenatal or early neonatal predictors of NOWS (though for exceptions see [@bib23]; [@bib38]; [@bib49]; [@bib55]; [@bib57], [@bib58]). Those studies that have examined early life predictors tend to use newborn neurobehavioral assessments, such as the NNNS. For example, [@bib55] examined newborns exposed to methadone *in utero* and found that infants who were ultimately treated for NOWS showed higher habituation scores, they were more aroused, excitable, and hypertonic compared to newborns who did not require treatment. In another study [@bib49] examined differences in NOWS outcomes between women using methadone for pain and those using methadone for drug treatment. They found that 11% of infants exposed to methadone because of maternal pain developed NOWS while 58% of infants exposed to methadone because of maternal substance use disorder developed NOWS.

NOWS symptom severity and even diagnosis could also be impacted by maternal sensitive caregiving. The percentage of newborns exposed to opioids prenatally who require pharmacological treatment to manage withdrawal symptoms ranges from 30 to 80% ([@bib61]). This variability in treatment is likely due to several factors including non-pharmacologic care (e.g., swaddling, skin-to-skin, and rooming in with the mother), as well as exposure to other substances such as nicotine ([@bib29]; [@bib60], [@bib61]). Several studies have recently published data demonstrating that rooming-in practices, breast feeding, and kangaroo care are related to a 7--60% decrease in the necessity for pharmacological treatment for NOWS and that these practices significantly reduce length of hospital stays ([@bib22]; [@bib60], [@bib61]). However, few studies have tested the efficacy of these nonpharmacological interventions using methodologically rigorous randomized controlled trials ([@bib60], [@bib61]), and no studies have examined mechanisms of effects (e.g., maternal sensitivity, changes in maternal HPA axis functioning), which are significant research gaps that are ripe for future research.

The long-term developmental consequences of prenatal exposure to opioids and related stressors are also unknown. Importantly, there are very few studies examining long-term neurodevelopmental consequences of infants exposed to opioids who then developed NOWS compared with exposed infants who did not develop NOWS. These studies are needed in order for clinicians to inform pregnant women about potential effects on infant development and to answer critical questions about whether opioids alter neurodevelopmental outcomes above and beyond associated stressors, such as exposure to poverty and parental psychopathology.

Finally, it will be important to consider whether the neurodevelopmental consequences of prenatal opioid exposure and correlated stressors differ between male and female fetuses. Current hypotheses suggest that males may be more at risk for experiencing developmental delays while females may experience more subtle effects that manifest later in life as mood disorders ([@bib47]). However, this literature is still quite limited.

In sum, developmental outcome studies of infants with prenatal opioid exposure are small and are plagued by methodological issues, including small sample sizes and lack of control for confounding variables such as exposure to poverty and maternal psychopathology. Thus, there is a critical gap in the literature that affects our ability to predict short-term effects of drug exposure. There is an even smaller literature on the long-term neurodevelopmental consequences of prenatal opioid exposure, particularly studies that examine differences between infants who develop NOWS compared to those that do not. Attention to these critical factors is important if we are to support the development of these underserved infants at risk for neurodevelopmental delays.
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